Virax Biolabs Group Ltd
NASDAQ:VRAX
Virax Biolabs Group Ltd
Research & Development
Virax Biolabs Group Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Virax Biolabs Group Ltd
NASDAQ:VRAX
|
Research & Development
-$1.8m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-82%
|
CAGR 10-Years
N/A
|
|
Virax Biolabs Group Ltd
Glance View
Virax Biolabs Group Ltd is a GB-based company operating in Health Care Providers & Services industry. Virax Biolabs Group Limited is a biotechnology company. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and med-tech and personal protective equipment (PPE) products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear, ViraxCare, and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Its products include antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. ViraxCare develops and distributes advanced medical devices, technology, and PPE globally. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus.
See Also
What is Virax Biolabs Group Ltd's Research & Development?
Research & Development
-1.8m
USD
Based on the financial report for Mar 31, 2025, Virax Biolabs Group Ltd's Research & Development amounts to -1.8m USD.
What is Virax Biolabs Group Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-82%
Over the last year, the Research & Development growth was -14%. The average annual Research & Development growth rates for Virax Biolabs Group Ltd have been -61% over the past three years , -82% over the past five years .
